ATE303159T1 - Null igf zur krebsbehandlung - Google Patents

Null igf zur krebsbehandlung

Info

Publication number
ATE303159T1
ATE303159T1 AT99950037T AT99950037T ATE303159T1 AT E303159 T1 ATE303159 T1 AT E303159T1 AT 99950037 T AT99950037 T AT 99950037T AT 99950037 T AT99950037 T AT 99950037T AT E303159 T1 ATE303159 T1 AT E303159T1
Authority
AT
Austria
Prior art keywords
igf
zero
cancer treatment
cancer
treatment
Prior art date
Application number
AT99950037T
Other languages
English (en)
Inventor
Desmond Mascarenhas
Original Assignee
Celtrix Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/399,120 external-priority patent/US7288516B1/en
Application filed by Celtrix Pharma filed Critical Celtrix Pharma
Application granted granted Critical
Publication of ATE303159T1 publication Critical patent/ATE303159T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT99950037T 1998-10-02 1999-09-29 Null igf zur krebsbehandlung ATE303159T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10274798P 1998-10-02 1998-10-02
US09/399,120 US7288516B1 (en) 1999-09-20 1999-09-20 Null IGF for the treatment of cancer
PCT/US1999/022681 WO2000020023A2 (en) 1998-10-02 1999-09-29 Null igf for the treatment of cancer

Publications (1)

Publication Number Publication Date
ATE303159T1 true ATE303159T1 (de) 2005-09-15

Family

ID=26799690

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99950037T ATE303159T1 (de) 1998-10-02 1999-09-29 Null igf zur krebsbehandlung

Country Status (8)

Country Link
EP (1) EP1117424B1 (de)
JP (1) JP2003522110A (de)
AT (1) ATE303159T1 (de)
AU (1) AU767141B2 (de)
CA (1) CA2345353C (de)
DE (1) DE69927041T2 (de)
HK (1) HK1040906B (de)
WO (1) WO2000020023A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU762351B2 (en) 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
AU2001263215A1 (en) 2000-05-16 2001-11-26 Genentech Inc. Method for treating cartilage disorders
EP1455807A2 (de) 2000-09-19 2004-09-15 Bioexpertise, Llc Verfahren für die verwendung von igf-bindunsprotein zur selektiven sensibilisierung von zielzellen in vivo
AUPR030900A0 (en) * 2000-09-22 2000-10-12 Queensland University Of Technology Growth factor complex
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310742A (en) * 1992-11-30 1994-05-10 Elias Alan N Uses for thioureylenes
WO1995016703A1 (en) * 1993-12-15 1995-06-22 Thomas Jefferson University Igf-1 analogs
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3

Also Published As

Publication number Publication date
HK1040906B (en) 2005-12-09
EP1117424A2 (de) 2001-07-25
CA2345353A1 (en) 2000-04-13
DE69927041T2 (de) 2006-06-14
WO2000020023A3 (en) 2000-07-06
AU767141B2 (en) 2003-10-30
JP2003522110A (ja) 2003-07-22
DE69927041D1 (de) 2005-10-06
HK1040906A1 (en) 2002-06-28
EP1117424B1 (de) 2005-08-31
CA2345353C (en) 2009-07-07
AU6277899A (en) 2000-04-26
WO2000020023A2 (en) 2000-04-13

Similar Documents

Publication Publication Date Title
DE60039752D1 (de) Herstellung tetravalenter antikörper
DE60020529D1 (de) Antikörper zur krebsbehandlung und -diagnose
NO20016007D0 (no) Rekombinant anti-CD40-antistoff og anvendelser derav
BR9714523A (pt) Tratamento de nefrite de lúpus com compostos anti-cd40l
BR9913645A (pt) Terapias combinadas para linfomas de células b compreendendo a administração de anticorpo anti-cd20
IL236404A0 (en) Doses for treatments using anti-erbb2 antibodies
WO1999057117A3 (de) Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
PH12012502439A1 (en) Antibodies to opgl
AU1049788A (en) Methods and peptides for the treatment of non-ige-mediated diseases
TR200000755T2 (tr) Karşıt olma-karşı gelme bozukluğunun tedavisi.
HUP9901908A2 (hu) p16 Expressziós konstrukciók és alkalmazásuk rákterápiában
DE69927041T2 (de) Null igf zur krebsbehandlung
DE69933468D1 (de) Adenovirus-vermittelte gentherapie
DE69520430D1 (de) Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon
EA200500934A1 (ru) Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний
Al‐Khenaizan et al. Ulcerative lichen planus of the sole: excellent response to topical tacrolimus
PT951553E (pt) Proteinas de e4 de adenovirus para unducao de morte celular
WO1999028460A3 (en) Molecules interacting with apoptin
ATE223721T1 (de) Edelfosin zur behandlung von hirntumoren
AU3308099A (en) Method for the treatment of pain, including chronic and female specific pain
YU13499A (sh) Primena 1-hidroksi-2-piridona za lečenje seboroitičnog dermatitisa
EP1152760A4 (de) Verwendung von 4-aminopyridin zur behandlung von peripheralen neuropathien
NO20020329L (no) Antitumor-antistoffer, proteiner og anvendelse derav
BR0212446A (pt) Uso de 4-piridilmetilftalazinas para tratamento de câncer
ATE222103T1 (de) Inklusionskomplexe in waessriger loesung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1117424

Country of ref document: EP

REN Ceased due to non-payment of the annual fee